Emerald Advisers LLC Sells 6,027 Shares of LivaNova PLC (NASDAQ:LIVN)

Emerald Advisers LLC reduced its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 0.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 746,513 shares of the company's stock after selling 6,027 shares during the quarter. LivaNova accounts for approximately 1.3% of Emerald Advisers LLC's holdings, making the stock its 26th largest holding. Emerald Advisers LLC owned about 1.37% of LivaNova worth $29,323,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. PNC Financial Services Group Inc. raised its holdings in shares of LivaNova by 29.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock valued at $292,000 after buying an additional 1,424 shares during the period. GAMMA Investing LLC raised its holdings in shares of LivaNova by 2,299.7% during the 1st quarter. GAMMA Investing LLC now owns 8,759 shares of the company's stock valued at $344,000 after buying an additional 8,394 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of LivaNova during the 4th quarter valued at about $2,772,000. Envestnet Asset Management Inc. raised its holdings in shares of LivaNova by 15.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock valued at $2,034,000 after buying an additional 5,850 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its holdings in shares of LivaNova by 147.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company's stock valued at $4,582,000 after buying an additional 58,911 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Down 5.0%

LIVN stock traded down $2.34 during mid-day trading on Friday, hitting $44.33. The stock had a trading volume of 545,629 shares, compared to its average volume of 628,541. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of -10.84 and a beta of 0.90. The company has a fifty day moving average of $44.53 and a 200 day moving average of $43.27. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $57.35.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Barclays dropped their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. Wolfe Research upgraded LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective for the company in a research note on Tuesday, May 20th. Robert W. Baird raised their price objective on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, LivaNova presently has a consensus rating of "Buy" and a consensus target price of $59.29.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.